October 14, 2024 01:58 PM EDT
FDA+

No­var­tis used a PRV to speed Kisqal­i's lat­est in­di­ca­tion, FDA says

Zachary Brennan

Senior Editor

No­var­tis used one of its pri­or­i­ty re­view vouch­ers (PRV) to speed the Sep­tem­ber ap­proval of Kisqali in ear­ly breast can­cer, the FDA said Mon­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times